DMACNasdaqPharmaceutical PreparationsFiscal year ends December 31
DiaMedica Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$7.87+0.30 (+3.96%)
Close on Oct 19, 2026
- Market cap
- $424.15M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.29 (+19.60%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $424.15M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 11.06
- Dividend yield
- –
- Free cash flow yield
- -7.44%
Fundamentals
- Net income
- -$37.54M
- EPS, diluted
- -$0.72
- Free cash flow
- -$31.54M
- Book value per share
- $0.71
- Diluted shares
- 54M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$39.23M
Net income
-$37.54M
EPS, diluted
-$0.72
Free cash flow
-$31.54M
Reported periodTrailing twelve months